LISTING OF THE CLAIMS:

1-23. (Previously Canceled)

24. (Original) Recombinant adeno-associated virus, prepared by applying a sample containing recombinant adeno-associated virus to an iodixanol gradient, and collecting said recombinant adeno-associated virus from said gradient.

25-30. (Previously Canceled)

31. (New) Purified recombinant adeno-associated virus, prepared by applying a crude sample containing recombinant adeno-associated virus to at least a first matrix comprising: heparin under conditions effective to permit binding of the virus to said first matrix; eluting the virus from the matrix; contacting the eluted virus with at least a first iodixanol gradient and collecting the virus.

32. (New) Purified recombinant adeno-associated virus (rAAV) prepared by applying a crude sample containing rAAV to an iodixanol gradient and collecting the rAAV from said gradient.

33. (New) A purified, high titer recombinant adeno-associated virus (rAAV) stock obtained by the steps of:

i) contacting a crude sample containing a population of rAAV particles with a heparin matrix under conditions effective to permit binding of the rAAV particles to the heparin;

ii) removing non-bound particles from the first matrix by a selective first elution;

iii) eluting the population of rAAV from the heparin matrix by a second elution;

iv) subjecting the population of rAAV from step iii) to an iodixanol gradient; and

v) collecting the rAAV from selected gradient fractions.

34. (New) The rAAV stock of claim 33 wherein the first matrix is heparin agarose type I.

35. (New) The rAAV stock of claim 33 wherein the first matrix is heparin agarose type II-S.

36. (New) The rAAV stock of claim 33 wherein the rAAV collected from selected gradient fractions is contacted with a hydrophobic matrix that interacts with hydrophobic species and collecting non-interacting virus eluted from the hydrophobic matrix.

37. (New) The rAAV stock of claim 36 wherein the hydrophobic matrix comprises agarose.

38. (New) The rAAV stock of claim 36 wherein the hydrophobic matrix comprises phenyl-agarose.

39. (New) The rAAV stock of claim 33 wherein the stock is obtained by the steps of I-v further comprising contacting the collected virus from the first iodixanol gradient with a second iodixanol gradient and collecting the virus from said second iodixanol gradient.

40. (New) The rAAV stock of claim 33 wherein the stock is obtained by the steps of I-v further comprising applying the virus collected from the first iodixanol gradient to a first cesium chloride gradient, and collecting the virus from the first cesium chloride gradient.

41. (New) The rAAV stock of claim 36 wherein collecting the stock further comprises applying the virus from the hydrophobic matrix to a second iodixanol gradient and collecting the virus from the second iodixanol gradient.

42. (New) The rAAV stock of claim 40 further comprising the step of applying the virus collected from the first cesium chloride gradient to a second cesium chloride equilibrium density gradient and collecting the virus from at least a first fraction of the second cesium chloride equilibrium density gradient.

43. (New) The rAAV stock of claim 33 wherein the heparin matrix is comprised within an HPLC column.

44. (New) The rAAV stock of claim 33, wherein the first iodixanol gradient comprises an about 15% iodixanol step, and about 25% iodixanol step, and about 40% iodixanol step, or an about 60% iodixanol step.

45. (New) The rAAV stock of claim 33, wherein at least the first iodixanol gradient further comprises NaCl.

46. (New) The rAAV stock of claim 33, wherein thevirus is eluted from the first matrix with a composition comprising at least about 1M NaCl.